教職人員
|
| 研究室成員 | : | 博士班：蔣心怡/黃鉉畯/楊宗諭/鄭孟宗/林柏叡 碩士班：李映璉,張詠淇/謝允晞,黃思涵,呂睿東 大學部：鄭靜茹, 黃浩軒 特助：巫賢修 曾參與的成員： 葉宗祐 (University of Wisconsin–Madison PhD)、邵麒軒(2022碩) 黃子祐 (University of Tennessee health science center) 林靖 (University of Michigan PhD)、蔡旻芙、劉雨琪(2023碩) 戴士軒 (2025碩) |
| 招生名額 | : | 博士班一名 碩士班二名 產博一名 |
| 徵才 | : | 學士級或碩士級研究助理 |
Development and optimization of a zein-coated inhalable HDAC inhibitor formulation as a potential treatment for idiopathic pulmonary fibrosis via three-fluid nozzle spray drying
(2026-03) WEI-REN KE ; SHENG-CHIEH HSIAO ; MENG-TSUNG CHENG ; CHAO-WU YU
Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent.
(2025-10) Huang, Hsuan-Chun ; Chen, Tse-Yu ; Yeh, Tsung-Yu ; Yu, Min-Hsuan ; Wu, Sian-Siou ; Li, Guang-Yi ; Chen, Bo-Yu ; MIAO-HSIA LIN ; Lin, Ching-Jung ; Hsu, Jui-Ling ; JIH-HWA GUH ; CHAO-WU YU
High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition.
(2025-08-01) Ke, Chiao-Hsu ; Huang, Mao-En ; Wu, Hsin-Yi ; CHAO-WU YU ; SHUEI-LIONG LIN ; Huang, Chih-Hung ; SHAU-PING LIN ; SHU-HAN YU ; CHEN-SI LIN
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation.
(2025) Lin, Ching ; Hsu, Jui-Ling ; Hsu, Yu-Tung ; Fan, Kuo-Chen ; Wu, Sian-Siou ; MIAO-HSIA LIN ; JIH-HWA GUH ; CHAO-WU YU
Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer
(2024-12) Wang, Kang-Li ; Yeh, Tsung-Yu ; Hsu, Pei-Chen ; Wong, Tzu-Hsuan ; Liu, Jia-Rong ; JI-WANG CHERN ; MIAO-HSIA LIN ; CHAO-WU YU
(2026-03) WEI-REN KE ; SHENG-CHIEH HSIAO ; MENG-TSUNG CHENG ; CHAO-WU YU
Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent.
(2025-10) Huang, Hsuan-Chun ; Chen, Tse-Yu ; Yeh, Tsung-Yu ; Yu, Min-Hsuan ; Wu, Sian-Siou ; Li, Guang-Yi ; Chen, Bo-Yu ; MIAO-HSIA LIN ; Lin, Ching-Jung ; Hsu, Jui-Ling ; JIH-HWA GUH ; CHAO-WU YU
High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition.
(2025-08-01) Ke, Chiao-Hsu ; Huang, Mao-En ; Wu, Hsin-Yi ; CHAO-WU YU ; SHUEI-LIONG LIN ; Huang, Chih-Hung ; SHAU-PING LIN ; SHU-HAN YU ; CHEN-SI LIN
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation.
(2025) Lin, Ching ; Hsu, Jui-Ling ; Hsu, Yu-Tung ; Fan, Kuo-Chen ; Wu, Sian-Siou ; MIAO-HSIA LIN ; JIH-HWA GUH ; CHAO-WU YU
Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer
(2024-12) Wang, Kang-Li ; Yeh, Tsung-Yu ; Hsu, Pei-Chen ; Wong, Tzu-Hsuan ; Liu, Jia-Rong ; JI-WANG CHERN ; MIAO-HSIA LIN ; CHAO-WU YU
Study the Effect and Mechanism of Novel Histone Deacetylase Inhibitors in Acute Kidney Injury-To-Chronic Kidney Disease
(2024-08-01～) SHUEI-LIONG LIN
Develop Novel Histone Deacetylase Inhibitors for Chronic Kidney Disease
(2023-08-01～) YUNG-MING CHEN
Develop Novel Histone Deacetylase Inhibitors for Chronic Kidney Disease
(2022-08-01～) YUNG-MING CHEN
Development of Novel Antibiotics against Bacterial Resistance through Characterizing the Bacterium-Specific Protein Phosphorylation and Acetylation Machinery
(2022-08-01～) MIAO-HSIA LIN
Novel Targeted Protein Degradation Platform: Small Molecule Anticancer Drug
(2022-01-01～) CHAO-WU YU
(2024-08-01～) SHUEI-LIONG LIN
Develop Novel Histone Deacetylase Inhibitors for Chronic Kidney Disease
(2023-08-01～) YUNG-MING CHEN
Develop Novel Histone Deacetylase Inhibitors for Chronic Kidney Disease
(2022-08-01～) YUNG-MING CHEN
Development of Novel Antibiotics against Bacterial Resistance through Characterizing the Bacterium-Specific Protein Phosphorylation and Acetylation Machinery
(2022-08-01～) MIAO-HSIA LIN
Novel Targeted Protein Degradation Platform: Small Molecule Anticancer Drug
(2022-01-01～) CHAO-WU YU